Chimerix has previously demonstrated that single doses of CMX001 provided excellent drug exposure and were well tolerated in healthy volunteers. CMX001 is being developed for smallpox under a licensing agreement with Gilead Sciences. The work is partially funded by a $36.1 million grant awarded to the company by the National Institutes of Allergy and Infectious Disease.
George Painter, president and CEO of Chimerix, said: “In addition to smallpox, we believe that CMX001 has great potential in treating other serious infections such as human papillomavirus and cytomegalovirus.”